Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | CDC42 | P60953 | 1/20 | 0.33 |
| ▸ | RAC1 | P63000 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5749701 | 1.00 | CYP17A1 (0.39) | CYP17A1KDM4ETHRBATMALDH1A1 | |
| SCHEMBL5754537 | 0.83 | CYP17A1 (0.44) | CYP17A1NPC1RAB9ACYP1A2 | |
| Fumaric Acid SCHEMBL5748408 | 0.82 | HPGDS (0.38) | CYP17A1KDM4ETHRBATMALDH1A1 | |
| Fumaric Acid SCHEMBL5748422 | 0.82 | HPGDS (0.38) | CYP17A1KDM4ETHRBATMALDH1A1 | |
| SCHEMBL5753491 | 0.80 | CYP17A1 (0.47) | CYP17A1KDM4ENPC1RAB9ACYP1A2 | |
| SCHEMBL5749704 | 0.79 | CYP17A1 (0.39) | CYP17A1KDM4EALDH1A1MEN1NPC1 | |
| SCHEMBL5750407 | 0.76 | ACSS2 (0.47) | CYP17A1NPC1RAB9ACYP1A2 | |
| Fumaric Acid SCHEMBL4029499 | 0.75 | CYP3A4 (0.58) | CYP17A1 | |
| Fumaric Acid SCHEMBL7266706 | 0.75 | CYP3A4 (0.58) | CYP17A1 | |
| SCHEMBL5754377 | 0.74 | CYP17A1 (0.41) | CYP17A1KDM4ENPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | MEN1 1335/4885KMT2A 1452/4885CYP17A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.